Literature DB >> 6255787

Comparative pharmacology of calcium antagonists: nifedipine, verapamil and diltiazem.

P D Henry.   

Abstract

Calcium antagonists (slow channel blocking agents) are a very heterogeneous group of agents with dissimilar structural, electrophysiologic and pharmacologic properties. Nifedipine is a potent, long-acting vasodilator that has proved highly efficacious in relieving anginal symptoms caused by coronary vasospasm. In vivo, it exerts no myocardial depressant effects and has no antiarrhythmic properties. Treatment with nifedipine can safely be combined with administration of a beta receptor blocking agent. VErapamil prolongs atrioventricular (A-V) conduction (A-H interval) in a dose-dependent manner. It is the drug of choice for the treatment of reentrant supraventricular arrhythmias, irrespective of whether reentry occurs within the A-V node or through an accessory pathway (the Wolff-Parkinson-White syndrome). Verapamil is only moderately effective as an antianginal agent. Diltiazem is efficacious for the treatment of angiospastic angina, but its value as an antiarrhythmic agent remains to be delineated.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6255787     DOI: 10.1016/0002-9149(80)90366-5

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  128 in total

1.  Calcium antagonists: A new class of therapeutic agents.

Authors:  Antonius Gunawan; Ali Massumi; Robert J. Hall
Journal:  Cardiovasc Dis       Date:  1981-09

2.  The effects of verapamil on cerebrospinal fluid pressure in surgical patients.

Authors:  T Nishikawa; A Namiki
Journal:  J Anesth       Date:  1987-09-01       Impact factor: 2.078

3.  Pharmacokinetics of nifedipine derived from a new retard tablet formulation.

Authors:  A Avgerinos; J W Gorrod
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1990 Oct-Dec       Impact factor: 2.441

Review 4.  Cor pulmonale in cystic fibrosis.

Authors:  M H Götz; O C Burghuber; U Salzer-Muhar; W Wolosczuk; M Weissel; E Hartter
Journal:  J R Soc Med       Date:  1989       Impact factor: 5.344

5.  Effects of short- and long-term administration of nifedipine on serum lipoprotein metabolism in patients with mild hypertension.

Authors:  J Sasaki; K Arakawa
Journal:  Cardiovasc Drugs Ther       Date:  1990-08       Impact factor: 3.727

6.  Action of nifedipine in ischemic heart disease.

Authors:  D D Miller; P Théroux; D D Waters; G B Pelletier
Journal:  Can Fam Physician       Date:  1983-04       Impact factor: 3.275

Review 7.  Diltiazem. A review of its pharmacological properties and therapeutic efficacy.

Authors:  M Chaffman; R N Brogden
Journal:  Drugs       Date:  1985-05       Impact factor: 9.546

8.  Alterations in angina threshold with nifedipine during pacing induced angina.

Authors:  P H Kramer; K Chatterjee; A Schwartz; K Swedberg; J L Rouleau; D Curran; L Blevins; W W Parmley
Journal:  Br Heart J       Date:  1984-09

9.  A unitary mechanism of calcium antagonist drug action.

Authors:  K M Murphy; R J Gould; B L Largent; S H Snyder
Journal:  Proc Natl Acad Sci U S A       Date:  1983-02       Impact factor: 11.205

10.  Tissue response selectivity of calcium antagonists is not due to heterogeneity of [3H]-nitrendipine binding sites.

Authors:  M R Bristow; R Ginsburg; J A Laser; B J McAuley; W Minobe
Journal:  Br J Pharmacol       Date:  1984-06       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.